Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings or view top-rated stocks.

3 equities research analysts have issued twelve-month target prices for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $3.00 to $10.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 155.0% from the stock's current price.
View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts.

Lexicon Pharmaceuticals' stock was trading at $1.91 at the beginning of 2023. Since then, LXRX stock has increased by 43.7% and is now trading at $2.7450.
View the best growth stocks for 2023 here.

Lexicon Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 6,450,000 shares, an increase of 30.8% from the April 30th total of 4,930,000 shares. Based on an average trading volume of 756,900 shares, the days-to-cover ratio is presently 8.5 days.
View Lexicon Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our LXRX earnings forecast.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company earned $0.02 million during the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 105.14% and a negative net margin of 87,620.63%. During the same quarter in the prior year, the firm posted $0.71 earnings per share.

ETFs with the largest weight of Lexicon Pharmaceuticals (NASDAQ:LXRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.98%), FMR LLC (2.76%), JPMorgan Chase & Co. (1.74%), Pinnacle Associates Ltd. (1.03%), Geode Capital Management LLC (0.91%) and State Street Corp (0.83%). Insiders that own company stock include International SCA Artal and James F Tessmer.
View institutional ownership trends.

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LXRX stock can currently be purchased for approximately $2.75.

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $520.34 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.